ESOC 2022 - ACTIMIS positive results - Presentation by Prof. M. Mazighi

ACTICOR BIOTECH, announced the presentation of positive results from the Phase 1b/2a study, ACTIMIS, in the treatment of acute ischemic stroke, at the 8th European Stroke Organisation Conference (ESOC) on Friday May 6, 2022.
On this occasion, Professor Mikael Mazighi, MD, PhD, Coordinating Investigator for ACTIMIS, presented the results of the ACTIMIS study during the "Closing Ceremony & Large Clinical Trials 2”:
"Glenzocimab, a Novel Antithrombotic, is Associated with Reduced Intracranial Hemorrhage and Mortality Rates when Combined with Standard-Of-Care Reperfusion Therapies: The ACTIMIS Study"

Видео ESOC 2022 - ACTIMIS positive results - Presentation by Prof. M. Mazighi канала Acticor Biotech